

WHAT IS CLAIMED IS:

1. An isolated polynucleotide selected from the group consisting of:
 - (a) a polynucleotide encoding a Ck β -4 polypeptide having the deduced amino acid sequence of SEQ ID NO. 2 or a fragment, analog or derivative of said polypeptide;
 - (b) a polynucleotide encoding a Ck β -4 polypeptide having the amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75848 or a fragment, analog or derivative of said polypeptide.
 - (c) a polynucleotide encoding an MCP-4 polypeptide comprising in sequence amino acid residues 28-93 of the MCP-4 polypeptide of SEQ ID NO. 3 having the deduced amino acid sequence of SEQ ID NO. 4 or a fragment, analog or derivative of said polypeptide; and
 - (d) a polynucleotide encoding an MCP-4 polypeptide having an amino acid sequence encoded by the cDNA contained in ATCC Deposit No. 75849 or a fragment, analog or derivative of said polypeptide.
2. The polynucleotide of Claim 1 wherein the polynucleotide is DNA.
3. The polynucleotide of Claim 1 wherein the polynucleotide is RNA.
4. The polynucleotide of Claim 1 wherein the polynucleotide is genomic DNA.
5. The polynucleotide of Claim 2 wherein said polynucleotide encodes Ck β -4 having the deduced amino acid sequence of SEQ ID NO. 2.
6. The polynucleotide of Claim 2 wherein said polynucleotide encodes MCP-4 having an amino acid sequence selected from the group consisting of residues 1-98, 17-98, 20-98, 22-98, 24-98, 28-98, 28-95 and 28-93 set out in SEQ ID NO. 4.

7. The polynucleotide of Claim 2 wherein said polynucleotide encodes a Ck β -4 polypeptide encoded by the cDNA of ATCC Deposit No. 75848.
8. The polynucleotide of Claim 2 wherein said polynucleotide encodes an MCP-4 polypeptide encoded by the cDNA of ATCC Deposit No. 75849.
9. The polynucleotide of Claim 1 having the coding sequence of Ck β -4 as shown in SEQ ID NO. 1.
10. The polynucleotide of Claim 1 having the coding sequence of MCP-4 as shown in SEQ ID NO. 3.
11. The polynucleotide of Claim 2 having the coding sequence of Ck β -4 deposited as ATCC Deposit No. 75848.
12. The polynucleotide of Claim 2 having the coding sequence of MCP-4 deposited as ATCC Deposit No. 75849.
13. A vector containing the DNA of Claim 2.
14. A host cell genetically engineered with the vector of Claim 13.
15. A process for producing a polypeptide comprising: expressing from the host cell of Claim 14 the polypeptide encoded by said DNA.
16. A process for producing cells capable of expressing a polypeptide comprising genetically engineering cells with the vector of Claim 13.
17. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having Ck β -4 activity.

18. An isolated DNA hybridizable to the DNA of Claim 2 and encoding a polypeptide having MCP-4 activity.

19. A polypeptide selected from the group consisting of (i) a Ck β -4 polypeptide having the deduced amino acid sequence of SEQ ID NO. 2 and fragments, analogs and derivatives thereof (ii) a Ck β -4 polypeptide encoded by the cDNA of ATCC Deposit No. 75848 and fragments, analogs and derivatives of said polypeptide (iii) an MCP-4 polypeptide having an amino acid sequence selected from the group consisting of residues 1-98, 17-98, 20-98, 22-98, 24-98, 28-98, 28-95 and 28-93 set of SEQ ID NO. 4 and fragments, analogs and derivatives thereof; and (iv) an MCP-4 polypeptide encoded by the cDNA of ATCC Deposit No. 75849 and fragments, analogs and derivatives of said polypeptide.

20. The polypeptide of Claim 19 wherein the polypeptide is Ck β -4 having the deduced amino acid sequence of SEQ ID NO. 2.

21. The polypeptide of Claim 19 wherein the polypeptide is an MCP-4 polypeptide selected from the group set out in (iii).

22. Antibodies against the polypeptides of Claim 19.

23. Antagonists against the polypeptides of Claim 19.

24. A method for the treatment of a patient having need of Ck β -4 comprising: administering to the patient a therapeutically effective amount of the a Ck β -4 polypeptide of claim 19.

25. A method for the treatment of a patient having need to inhibit Ck β -4 comprising: administering to the patient a therapeutically effective amount of a Ck β -4 antagonist of claim 23.

26 A method for the treatment of a patient having need of MCP-4 comprising: administering to the patient a therapeutically effective amount of an MCP-4 polypeptide of claim 19.

27 A method for the treatment of a patient having need to inhibit MCP-4 comprising: administering to the patient a therapeutically effective amount of the antagonist of claim 23.

28. A composition comprising a polypeptide of claim 19 and an acceptable carrier.

29. The method of claim 24 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.

30. The method of claim 26 wherein said therapeutically effective amount of the polypeptide is administered by providing to the patient DNA encoding said polypeptide and expressing said polypeptide *in vivo*.